文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

西班牙HIV研究网络队列中SARS-CoV-2血清阳性率及相关因素

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
PubMed 文献 · Clin Microbiol Infect · 2021-06-26

本研究为西班牙HIV研究网络的横断面研究,纳入1076名HIV感染者,2020年4月至9月采集血浆检测SARS-CoV-2抗体。血清阳性率为8.5%(95%CI 6.9-10.3%),45.0%感染无症状。拉丁美洲出生与血清阳性独立相关(aOR 2.30),而TDF/FTC方案相比TAF/FTC与较低风险相关(aOR 0.49)。

要点

  • HIV感染者SARS-CoV-2血清阳性率为8.5%,近半数感染无症状。
  • 拉丁美洲出生者血清阳性风险增高(aOR 2.30)。
  • TDF/FTC方案可能降低SARS-CoV-2感染风险(aOR 0.49)。

核心结论

  • HIV感染者中SARS-CoV-2感染多无症状,拉丁美洲出生增加血清阳性风险,TDF/FTC可能预防感染。

研究设计与样本

  • 西班牙HIV研究网络队列的横断面研究,连续纳入1076名HIV感染者,2020年4月1日至9月30日采集血浆检测SARS-CoV-2抗体。

主要发现

  • 1076名参与者中91人检出SARS-CoV-2抗体,血清阳性率8.5%(95%CI 6.9-10.3%)。
  • 45例感染(45.0%)为无症状。
  • 拉丁美洲出生对比西班牙出生:aOR 2.30(95%CI 1.41-3.76,p 0.001)。
  • TDF/FTC对比TAF/FTC作为N(t)RTI骨架:aOR 0.49(95%CI 0.26-0.94,p 0.031)。

关键数值与推荐

  • 血清阳性率8.5%(95%CI 6.9-10.3%),无症状比例45.0%。
  • 拉丁美洲出生aOR 2.30(95%CI 1.41-3.76,p 0.001)。
  • TDF/FTC方案aOR 0.49(95%CI 0.26-0.94,p 0.031)。

临床怎么用

  • 对HIV感染者应关注SARS-CoV-2无症状感染,尤其拉丁美洲出生者。
  • 含TDF/FTC方案可能降低SARS-CoV-2感染风险,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH). METHODS: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection. RESULTS: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm3, 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031). CONCLUSIONS: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Berenguer J, Díez C, Martín-Vicente M, et al. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clin Microbiol Infect. 2021. PMID: 34186209. doi:10.1016/j.cmi.2021.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。